Purple Biotech completes toxicology study of IM1240

Purple Biotech (PPBT) announced successful completion of a non-human primates toxicology study of IM1240, a tri-specific antibody from its CAPTN-3 platform that targets 5T4, a tumor-specific antigen expressed on multiple solid tumors. “The Study demonstrated that IM1240’s proprietary capping technology enabled dosing at levels up to 300-fold higher than a non-capped comparator, with significantly reduced immune-related toxicity, including minimal cytokine release. These results highlight the unique safety profile of this approach, which may address a key limitation of certain current T cell engagers, where cytokine release syndrome can restrict dosing,” the company said.